Jpmorgan Chase & CO Mainz Biomed N.V. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MYNZ
# of Institutions
11Shares Held
176KCall Options Held
0Put Options Held
0-
Vontobel Holding Ltd.45KShares$11,2500.0% of portfolio
-
Northern Trust Corp Chicago, IL29.9KShares$7,4830.0% of portfolio
-
Steward Partners Investment Advisory, LLC29KShares$7,2500.0% of portfolio
-
Two Sigma Securities, LLC New York, NY23.5KShares$5,8780.0% of portfolio
-
Geode Capital Management, LLC Boston, MA15.2KShares$3,7970.0% of portfolio
About MAINZ BIOMED N.V.
- Ticker MYNZ
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 14,483,000
- Market Cap $3.62M
- Description
- Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments...